IL307303A - A pyridazine compound for NLRP3 inhibition - Google Patents

A pyridazine compound for NLRP3 inhibition

Info

Publication number
IL307303A
IL307303A IL307303A IL30730323A IL307303A IL 307303 A IL307303 A IL 307303A IL 307303 A IL307303 A IL 307303A IL 30730323 A IL30730323 A IL 30730323A IL 307303 A IL307303 A IL 307303A
Authority
IL
Israel
Prior art keywords
pyridazine compounds
inhibiting nlrp3
nlrp3
inhibiting
pyridazine
Prior art date
Application number
IL307303A
Other languages
English (en)
Hebrew (he)
Inventor
St?phane DORICH
Jason Burch
Miguel St-Onge
Amandine Chefson
Alexandre C?T?
Ramsay Beveridge
St?Phane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
St?phane DORICH
Jason Burch
St Onge Miguel
Amandine Chefson
Alexandre C?T?
Ramsay Beveridge
St?Phane Ciblat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc, St?phane DORICH, Jason Burch, St Onge Miguel, Amandine Chefson, Alexandre C?T?, Ramsay Beveridge, St?Phane Ciblat filed Critical Ventus Therapeutics U S Inc
Publication of IL307303A publication Critical patent/IL307303A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL307303A 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition IL307303A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof
PCT/US2022/023893 WO2022216971A1 (en) 2021-04-07 2022-04-07 Pyridazine compounds for inhibiting nlrp3

Publications (1)

Publication Number Publication Date
IL307303A true IL307303A (en) 2023-11-01

Family

ID=81385286

Family Applications (2)

Application Number Title Priority Date Filing Date
IL307303A IL307303A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition
IL308378A IL308378A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL308378A IL308378A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition

Country Status (15)

Country Link
US (10) US11319319B1 (enExample)
EP (3) EP4331668A3 (enExample)
JP (2) JP7620120B2 (enExample)
KR (1) KR20230167394A (enExample)
CN (2) CN117510495A (enExample)
AU (3) AU2022256052B2 (enExample)
BR (1) BR112023020483A2 (enExample)
CA (1) CA3214676A1 (enExample)
CL (2) CL2023002973A1 (enExample)
CO (1) CO2023013356A2 (enExample)
IL (2) IL307303A (enExample)
MX (2) MX2023011576A (enExample)
PE (1) PE20240765A1 (enExample)
TW (2) TW202330522A (enExample)
WO (1) WO2022216971A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
AR126053A1 (es) 2021-06-04 2023-09-06 Hoffmann La Roche Derivados de triazina
US20240294542A1 (en) * 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
DK4363406T3 (da) * 2021-07-02 2025-12-01 Astrazeneca Ab Nlrp3-inflammasomhæmmere
IL310264A (en) 2021-07-21 2024-03-01 Nico Therapeutics Inc Annulated pyridazine compound
WO2023028534A1 (en) * 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. Inhibitors of nlrp3
CA3233482A1 (en) * 2021-09-30 2023-04-06 Origiant Pharmaceutical Co., Ltd Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
CN116102535A (zh) * 2021-10-22 2023-05-12 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
AU2023238121A1 (en) * 2022-03-25 2024-10-10 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
AU2023245348A1 (en) * 2022-03-31 2024-09-12 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
KR20250036233A (ko) * 2022-07-14 2025-03-13 에이씨 이뮨 에스에이 Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
US20240124451A1 (en) * 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
JP2025023868A (ja) * 2022-09-23 2025-02-17 メルク・シャープ・アンド・ドーム・エルエルシー Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
WO2024090469A1 (ja) 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024097629A1 (en) * 2022-10-31 2024-05-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
TW202419090A (zh) * 2022-11-04 2024-05-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3炎症小體抑制劑及其應用
CN120225506A (zh) * 2022-11-25 2025-06-27 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
EP4637746A1 (en) * 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
CN120584106A (zh) 2022-12-28 2025-09-02 阿斯利康(瑞典)有限公司 Nlrp3炎性小体抑制剂
CN120435457A (zh) 2022-12-28 2025-08-05 阿斯利康(瑞典)有限公司 Nlrp3炎性小体抑制剂的结晶形式、化学方法和化学化合物
EP4644380A1 (en) * 2022-12-28 2025-11-05 Changchun Genescience Pharmaceutical Co., Ltd. Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
CN120569372A (zh) 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
CN121001996A (zh) 2023-01-31 2025-11-21 詹森药业有限公司 作为nlrp3抑制剂的吡啶-2(1h)-酮和嘧啶-4(3h)-酮
EP4658649A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors
CN120981462A (zh) 2023-01-31 2025-11-18 詹森药业有限公司 咪唑并[1,2-d][1,2,4]三嗪作为NLRP3抑制剂
CN120957980A (zh) 2023-01-31 2025-11-14 詹森药业有限公司 作为nlrp3抑制剂的2-(哒嗪-3-基)-5-(三氟甲基)苯酚
EP4658654A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV Pyrrolo[1,2-d][1,2,4]triazines and pyrazolo[1,5-d] [1,2,4]triazines as nlrp3 inhibitors
CN120435466A (zh) * 2023-02-17 2025-08-05 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2025006681A2 (en) * 2023-06-27 2025-01-02 Viva Star Biosciences (Us) Inc. Substituted pyridazine compounds as inhibitors of nlrp3 activity and therapeutic uses thereof
CN119462517A (zh) * 2023-08-11 2025-02-18 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
CN117143027B (zh) * 2023-08-31 2024-12-20 四川大学 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025059481A1 (en) * 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
KR20250074627A (ko) 2023-11-20 2025-05-27 벤투스 테라퓨틱스 유에스 인코포레이티드 NLRP3을 억제하기 위한 5-클로로-2-(4-((2-하이드록시-2-메틸프로필)아미노)피리도[3,4-d]피리다진-1-일)페놀의 고형 유리염기 형태 및 이의 용도
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
TW202535370A (zh) 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303061A (enExample) * 1969-05-03 1973-01-17
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
ATE115136T1 (de) 1990-03-30 1994-12-15 Mitsubishi Chem Ind 4-phenylphthalazin-derivate.
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
JP2668163B2 (ja) 1992-01-23 1997-10-27 ファイザー インク． コレステロール血症および抗アテローム動脈硬化症薬としての４−アリール−３−（ヘテロアリールウレイド）−１，２−ジヒドロ−２−オキソ−キノリン誘導体
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
DE4417746A1 (de) 1994-05-20 1995-11-23 Bayer Ag Neue Farbstoffe zum Massefärben von Kunststoffen
DE69533057T2 (de) * 1994-08-09 2005-06-16 Eisai Co., Ltd. Kondensierte pyridazinverbindungen
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
CA2258079A1 (en) 1996-08-20 1998-02-26 Mayu Shibazaki Remedy for erection failure comprising fused pyridazine compound
US20030124053A1 (en) 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
AU5614198A (en) 1996-12-18 1998-07-15 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
US6486158B1 (en) 1998-08-14 2002-11-26 Cell Pathways, Inc. [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
CN1161341C (zh) 1999-03-22 2004-08-11 布里斯托尔-迈尔斯斯奎布公司 cGMP磷酸二酯酶的稠合吡啶并哒嗪抑制剂
JP2005510568A (ja) 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク アリール基が結合したアザポリサイクリック化合物
WO2004099158A1 (en) 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
US7087621B2 (en) 2003-09-05 2006-08-08 Bristol-Myers Squibb Company Benzo- and azabenzodithiazole compounds
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
JP5221952B2 (ja) 2004-05-08 2013-06-26 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド ３−アリール−５，６−ジ置換ピリダジン類
KR101179382B1 (ko) 2004-06-09 2012-09-03 에릭 엠. 카레이라 모노포스핀 화합물, 그의 전이 금속 착체 및 상기 착체를비대칭 촉매로서 사용하는 광학 활성 화합물의 제조 방법
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
CA2622677A1 (en) 2005-09-23 2007-04-05 Richard Schumacher Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
FR2891828B1 (fr) 2005-10-12 2007-12-21 Sanofi Aventis Sa Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
AU2006311851A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-A2 inhibitors
WO2007056281A2 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
WO2007056580A2 (en) 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
JP2009120486A (ja) 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
AU2007208351C1 (en) 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US8658801B2 (en) 2006-02-16 2014-02-25 Syngenta Crop Protection, Llc Pesticides containing a bicyclic bisamide structure
CA2660114A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2008128968A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
AU2008248165B2 (en) 2007-05-04 2011-12-08 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US9023490B2 (en) 2007-06-15 2015-05-05 Versitech Limited Extended pi-conjugated platinum (II) complexes
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
WO2009038812A1 (en) 2007-09-20 2009-03-26 Amgen Inc. Condensed piperidine derivatives useful as vanilloid receptor ligands
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
WO2009126947A2 (en) 2008-04-11 2009-10-15 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
AU2009246626A1 (en) 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
WO2009152909A1 (en) 2008-06-16 2009-12-23 Merck Patent Gmbh Quinoxalinedione derivatives
WO2009157386A1 (ja) 2008-06-25 2009-12-30 住友化学株式会社 光学活性アミン化合物の製造方法
US20110218211A1 (en) 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
WO2010036544A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
MX2011009213A (es) 2009-03-02 2011-12-14 Sirtris Pharmaceuticals Inc Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CN102369199A (zh) 2009-04-01 2012-03-07 巴斯夫欧洲公司 用于防治无脊椎动物害虫的异*唑啉化合物
EP2416772A1 (en) 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
WO2010117935A1 (en) 2009-04-06 2010-10-14 Schering Corporation Compounds and methods for antiviral treatment
WO2010151791A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102958930B (zh) 2010-06-28 2018-04-27 默克专利有限公司 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
MX2012015143A (es) 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
US20130165440A1 (en) 2010-09-14 2013-06-27 Exelixis, Inc. JAK1 Inhibitors
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
CN103534237B (zh) 2011-05-18 2016-06-15 先正达参股股份有限公司 基于芳硫基乙酰胺衍生物的杀虫化合物
JP5978302B2 (ja) 2011-08-08 2016-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ リゾホスファチジン酸アンタゴニストとしての（ｎ−ベンズイミダゾール−２−イル）−シクロプロパンカルボキサミド
JP2014524459A (ja) 2011-08-25 2014-09-22 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト シロアリおよびアリの防除方法
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
WO2013176698A1 (en) 2012-05-22 2013-11-28 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9675073B2 (en) 2012-11-21 2017-06-13 Syngenta Participations Ag Insecticidal compounds based on N-arylsulfanylmethylcarboxamidearylthiosulfonamides derivatives
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014079935A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on arylthioacetamide derivatives
WO2014086737A1 (de) 2012-12-06 2014-06-12 Bayer Cropscience Ag Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide
TW201439060A (zh) 2013-02-27 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
GB201311953D0 (en) 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN106458912B (zh) 2014-04-04 2020-10-27 辉瑞公司 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
CN103992311B (zh) 2014-06-20 2017-01-25 东南大学 Hedgehog信号通路抑制剂
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
RU2741387C2 (ru) 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
US20180093956A1 (en) 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
KR102727059B1 (ko) 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
CN113750101A (zh) 2015-12-10 2021-12-07 Ptc医疗公司 用于治疗亨廷顿病的方法
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018067442A8 (pt) 2016-02-12 2024-01-09 Pharmaxis Ltd Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3236267B1 (en) 2016-04-18 2021-09-08 Roche Diagnostics GmbH Decapper and apparatus
AU2017254523B2 (en) 2016-04-18 2021-09-02 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
AU2017253937B2 (en) 2016-04-18 2021-08-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
WO2018031680A1 (en) 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
KR102507847B1 (ko) * 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
WO2018172925A1 (en) 2017-03-23 2018-09-27 Vitas Pharma Research Pvt Ltd Inhibitors of dna gyrase for treatment of bacterial infections
KR101943428B1 (ko) 2017-03-24 2019-01-30 엘티소재주식회사 유기 발광 소자 및 유기 발광 소자의 유기물층용 조성물
WO2018174678A1 (ko) 2017-03-24 2018-09-27 희성소재(주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
WO2018221433A1 (ja) 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
TWI684637B (zh) 2017-07-20 2020-02-11 南韓商Ｌｇ化學股份有限公司 化合物及包括此化合物的有機發光裝置
TW201910316A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CA3073333A1 (en) 2017-08-21 2019-02-28 Merck Patent Gmbh Bezimidazole derivatives as adenosine receptor antagonists
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
WO2020021015A1 (en) 2018-07-26 2020-01-30 Esteve Pharmaceuticals, S.A. New imidazopyridine derivatives for treating pain and pain related conditions
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN119320388A (zh) 2019-02-04 2025-01-17 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR102721075B1 (ko) 2019-02-15 2024-10-24 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
UY38687A (es) * 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
JP7738910B2 (ja) * 2020-03-27 2025-09-16 テンヴィー・セラピューティクス，インコーポレーテッド 置換ピリダジン化合物
JP2023527010A (ja) 2020-05-28 2023-06-26 ヤンセン ファーマシューティカ エヌ．ベー． 化合物
MX2022015812A (es) 2020-06-09 2023-04-05 Pardes Biosciences Inc Inhibidores de cisteina proteasas y sus metodos de uso.
WO2022135567A1 (zh) 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
WO2022166890A1 (zh) 2021-02-08 2022-08-11 南京明德新药研发有限公司 取代的哒嗪苯酚类衍生物
IL307157A (en) 2021-04-07 2023-11-01 Forma Therapeutics Inc Ubiquitin-specific protease 1 (USP1) inhibition
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022230912A1 (ja) 2021-04-28 2022-11-03 アステラス製薬株式会社 置換トリアジン化合物
BR112023022471A2 (pt) 2021-04-29 2024-01-16 Janssen Pharmaceutica Nv Derivados de ftalazinona como inibidores de inflamassoma nlrp3
FI4337652T3 (fi) 2021-05-12 2025-06-20 Hoffmann La Roche NLRP3:n estäjiä
AR126053A1 (es) 2021-06-04 2023-09-06 Hoffmann La Roche Derivados de triazina
US20240294542A1 (en) 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
JP2024529839A (ja) 2021-06-29 2024-08-14 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
DK4363406T3 (da) 2021-07-02 2025-12-01 Astrazeneca Ab Nlrp3-inflammasomhæmmere
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
IL310264A (en) 2021-07-21 2024-03-01 Nico Therapeutics Inc Annulated pyridazine compound
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
KR20240052009A (ko) 2021-08-25 2024-04-22 자이두스 라이프사이언시즈 리미티드 신경염증성 장애의 치료
WO2023028534A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. Inhibitors of nlrp3
CA3233482A1 (en) 2021-09-30 2023-04-06 Origiant Pharmaceutical Co., Ltd Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
AR127386A1 (es) 2021-10-19 2024-01-17 Hoffmann La Roche Compuestos heteroarilicos bicíclicos fusionados útiles como inhibidores de nlrp3
CN116102535A (zh) 2021-10-22 2023-05-12 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
JP2024540445A (ja) 2021-11-17 2024-10-31 エフ． ホフマン－ラ ロシュ アーゲー 複素環式ｎｌｒｐ３阻害剤
WO2023088987A1 (en) 2021-11-19 2023-05-25 F. Hoffmann-La Roche Ag Pyridazine derivatives as inhibitors of nlrp3
US20250074888A1 (en) 2021-12-29 2025-03-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
WO2023131277A1 (zh) 2022-01-07 2023-07-13 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
CN116726020A (zh) 2022-03-08 2023-09-12 上海拓界生物医药科技有限公司 一类含哒嗪的化合物的药物组合物及其医药用途
AU2023234527A1 (en) 2022-03-15 2024-10-31 Zomagen Biosciences Ltd Nlrp3 modulators
AU2023238121A1 (en) 2022-03-25 2024-10-10 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives
AU2023245348A1 (en) 2022-03-31 2024-09-12 Hangzhou Highlightll Pharmaceutical Co., Ltd Nlrp3 inflammasome inhibitors
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
CN116969920A (zh) 2022-04-29 2023-10-31 上海辉启生物医药科技有限公司 稠合哒嗪衍生物及其制备方法与医药用途
IL316607A (en) 2022-05-13 2024-12-01 Neumora Therapeutics Inc NLRP3 inflammasome modulators and related products and methods
WO2023232917A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Novel compounds
WO2024006559A1 (en) 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
WO2024012551A1 (zh) 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
KR20250036233A (ko) 2022-07-14 2025-03-13 에이씨 이뮨 에스에이 Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체
EP4558499A1 (en) 2022-07-21 2025-05-28 F. Hoffmann-La Roche AG Nlrp3 inhibitors
JP2025526423A (ja) 2022-07-28 2025-08-13 エーシー・イミューン・エス・アー 新規化合物
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
JP2025526692A (ja) 2022-08-10 2025-08-15 武田薬品工業株式会社 複素環式化合物
CN116789674B (zh) 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
US20240124451A1 (en) 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024097629A1 (en) 2022-10-31 2024-05-10 Ventus Therapeutics U.S., Inc. Bridged bicyclic heterocycloalkyl pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 inhibitors
WO2024097598A1 (en) 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3
TW202419090A (zh) 2022-11-04 2024-05-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3炎症小體抑制劑及其應用
WO2024094150A1 (en) 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
WO2024099992A1 (en) 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
PE20251675A1 (es) 2022-11-09 2025-06-30 Hoffmann La Roche Derivados de triazinona como inhibidores de nlrp3
CN120152964A (zh) 2022-11-09 2025-06-13 豪夫迈·罗氏有限公司 作为nlrp3抑制剂的三嗪酮衍生物
CN118056822A (zh) 2022-11-18 2024-05-21 正大天晴药业集团股份有限公司 一种哒嗪并环化合物及其用途
CN120225506A (zh) 2022-11-25 2025-06-27 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
PE20251845A1 (es) 2022-12-07 2025-07-17 Hoffmann La Roche Compuestos novedosos como moduladores de la inhibicion de nlrp3
AR131282A1 (es) 2022-12-08 2025-03-05 Hoffmann La Roche Compuestos novedosos
EP4637746A1 (en) 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
EP4638434A1 (en) 2022-12-23 2025-10-29 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
CN120379995A (zh) 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
EP4644380A1 (en) 2022-12-28 2025-11-05 Changchun Genescience Pharmaceutical Co., Ltd. Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
CN120584106A (zh) 2022-12-28 2025-09-02 阿斯利康(瑞典)有限公司 Nlrp3炎性小体抑制剂
AU2023414924A1 (en) 2022-12-30 2025-07-03 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
AU2024206808A1 (en) 2023-01-03 2025-07-17 Kodiak Sciences Inc. Organic compounds as nlrp3 inhibitors
CN120981462A (zh) 2023-01-31 2025-11-18 詹森药业有限公司 咪唑并[1,2-d][1,2,4]三嗪作为NLRP3抑制剂
CN121001996A (zh) 2023-01-31 2025-11-21 詹森药业有限公司 作为nlrp3抑制剂的吡啶-2(1h)-酮和嘧啶-4(3h)-酮
CN120957980A (zh) 2023-01-31 2025-11-14 詹森药业有限公司 作为nlrp3抑制剂的2-(哒嗪-3-基)-5-(三氟甲基)苯酚
EP4658654A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV Pyrrolo[1,2-d][1,2,4]triazines and pyrazolo[1,5-d] [1,2,4]triazines as nlrp3 inhibitors
EP4658649A1 (en) 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors

Also Published As

Publication number Publication date
KR20230167394A (ko) 2023-12-08
US20240174668A1 (en) 2024-05-30
WO2022216971A1 (en) 2022-10-13
AU2025213656A1 (en) 2025-08-28
US20230159526A1 (en) 2023-05-25
CL2023002973A1 (es) 2024-03-08
CO2023013356A2 (es) 2023-10-30
AU2023263450B2 (en) 2025-04-17
EP4320102A1 (en) 2024-02-14
US12312350B2 (en) 2025-05-27
EP4537900A3 (en) 2025-07-16
US20240368160A1 (en) 2024-11-07
BR112023020483A2 (pt) 2023-11-21
JP2024514837A (ja) 2024-04-03
EP4537900A2 (en) 2025-04-16
TW202304905A (zh) 2023-02-01
US12410167B2 (en) 2025-09-09
CN117510495A (zh) 2024-02-06
US20220340567A1 (en) 2022-10-27
AU2022256052A1 (en) 2023-11-16
EP4331668A3 (en) 2024-06-05
JP2024050527A (ja) 2024-04-10
CN117500792A (zh) 2024-02-02
CL2024001964A1 (es) 2024-12-06
MX2024000820A (es) 2024-02-06
US11319319B1 (en) 2022-05-03
AU2023263450C1 (en) 2025-10-30
US20240199606A1 (en) 2024-06-20
US20240360129A1 (en) 2024-10-31
PE20240765A1 (es) 2024-04-17
AU2023263450A1 (en) 2023-11-23
US12441728B2 (en) 2025-10-14
IL308378A (en) 2024-01-01
US20250250270A1 (en) 2025-08-07
US12351578B2 (en) 2025-07-08
US20240360128A1 (en) 2024-10-31
CA3214676A1 (en) 2022-10-13
US20240158396A1 (en) 2024-05-16
US12281112B2 (en) 2025-04-22
WO2022216971A9 (en) 2022-12-08
JP7620120B2 (ja) 2025-01-22
MX2023011576A (es) 2023-11-09
AU2022256052B2 (en) 2025-06-05
EP4331668A2 (en) 2024-03-06
TW202330522A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
IL308378A (en) A pyridazine compound for NLRP3 inhibition
IL316450A (en) Compounds for inhibiting KIF18A
GB201914860D0 (en) Inhibitor compounds
GB202008201D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
GB202200735D0 (en) Compounds
GB202004960D0 (en) Inhibitor compounds
IL288292A (en) Oxathiazine compounds for gapdh inhibition
GB202208643D0 (en) Compounds
GB201905328D0 (en) Inhibitor compounds
HK40101148A (en) Pyridazine compounds for inhibiting nlrp3
GB202110373D0 (en) Inhibitor compounds
GB202208151D0 (en) Compounds
GB202201996D0 (en) Compounds
GB202117224D0 (en) Inhibitor compounds
GB202112240D0 (en) Inhibitor compounds
GB202107325D0 (en) Inhibitor compounds
GB202104781D0 (en) Inhibitor compounds
GB202016964D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
GB202008205D0 (en) Inhibitor compounds
GB202307924D0 (en) Inhibitor compounds
GB202306601D0 (en) Inhibitor compounds
GB202300881D0 (en) Inhibitor compounds
GB202215245D0 (en) Inhibitor compounds